The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing

Sarahrudi, Kambiz; Kaiser, Georg; Thomas, Anita; Michel, Mark; Wolf, Harald; Mousavi, Mehdi; Aharinejad, Seyedhossein

doi:10.1007/s00264-011-1392-6

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies indicate a delay of callus remodelling due to thromboprophylaxis with UH and LMW heparin [ 9 , 17 ]. So far there is no study which investigated the effect of the new oral Factor Xa inhibitor rivaroxaban on fracture healing.…”

Section: Discussionmentioning

confidence: 99%

Rivaroxaban does not impair fracture healing in a rat femur fracture model: an experimental study

Klüter¹,

Weuster²,

Brüggemann³

et al. 2015

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundThe prescription of the oral anticoagulant rivaroxaban to prevent thromboembolic episodes associated with orthopaedic surgery has dramatically increased since it was introduced. Rivaroxaban is beeing prescribed although recent in-vitro studies revealed that it impaired osteoblast metabolism. In this study we analysed the effect of rivaroxaban on fracture healing in a rat femur fracture model.MethodsFemur fractures were created by a 3-point-bending device in 48 Wistar rats and subsequently stabilized by intramedullary nailing. After the surgical procedure animals were randomised into four groups. Two groups were fed with 3 mg rivaroxaban per kg body weight per day and two control groups were fed with chow only. Animals were euthanized 28 or 49 days after surgical procedure. Femurs underwent undecalcified histologic staining micro CT scanning and biomechanical testing. The statistical significance was evaluated using one-way Anova with Bonferroni correction.ResultsMicro CT-scans revealed significantly increased volume of bone tissue in the fracture zone between day 28 and 49. During the same time callus volume decreased significantly. Comparing the fracture zone of the rivaroxaban group to the control group the treated group revealed a larger callus and a marginal increase of the tissue mineral density. The torsional rigidity was not influenced by the treatment of rivaroxaban.ConclusionIn the present study we were able to demonstrate that rivaroxaban does not impair fracture healing in a rat femur fracture model. Considering the fact that low molecular weight heparins delay fracture healing significantly, rivaroxaban might be an improved alternative.

show abstract

Section: Discussionmentioning

confidence: 99%

Rivaroxaban does not impair fracture healing in a rat femur fracture model: an experimental study

Klüter¹,

Weuster²,

Brüggemann³

et al. 2015

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…Furthermore, the study of Sarahrudi et al was the first comparative systematic measurement of VEGF serum levels in patients receiving enoxaparin. In this study no significant difference of the VEGF expression was observed [ 57 ].…”

Section: Discussionmentioning

confidence: 84%

“…Finally, Sarahrudi et al [ 57 ] first analyzed the alterations in the expression of osteogenic growth factors in patients with long bone fracture treated with enoxaparin. They measured (M-CSF, VEGF and TGF- β1) after treatment with enoxaparin and they observed significant differences of the expression of growth factors without any influence on fracture healing process.…”

Section: Literature Reviewmentioning

confidence: 99%

The Effect of Low Molecular Weight Heparins on Fracture Healing

Kapetanakis¹,

Nastoulis²,

Demesticha³

et al. 2015

TOORTHJ

View full text Add to dashboard Cite

Venous Thromboembolism is a serious complication in the trauma patient. The most commonly studied and used anticoagulant treatment in prophylaxis of thrombosis is heparin. The prolonged use of unfractionated heparin has been connected with increased incidence of osteoporotic fractures. Low molecular-weight-heparins (LMWHs) have been the golden rule in antithrombotic therapy during the previous two decades as a way to overcome the major drawbacks of unfractioned heparin. However there are few studies reporting the effects of LMWHs on bone repair after fractures. This review presents the studies about the effects of LMWHs on bone biology (bone cells and bone metabolism) and underlying the mechanisms by which LMWHs may impair fracture healing process. The authors’ research based on literature concluded that there are no facts and statistics for the role of LMWHs on fracture healing process in humans and the main body of evidence of their role comes from in vitro and animal studies. Further large clinical studies designed to compare different types of LMWHs, in different dosages and in different patient or animal models are needed for exploring the effects of LMWHs on fracture healing process.

show abstract

Toward the Clinical Use of Circulating Biomarkers Predictive of Bone Union

Chaverri

Vives

2017

Biomark. Med.

View full text Add to dashboard Cite

Current methods for diagnosis of bone healing after treatment of trauma injuries rely on clinical findings and the use of imaging methodologies that provide conclusive results but only at mid/long-term post-intervention. In this Perspective we present and discuss incipient evidence on biomarkers that may serve for monitoring the progression of bone healing as well as predicting eventual nonunion outcomes.

show abstract

The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing

Cited by 4 publications

References 27 publications

Rivaroxaban does not impair fracture healing in a rat femur fracture model: an experimental study

Rivaroxaban does not impair fracture healing in a rat femur fracture model: an experimental study

The Effect of Low Molecular Weight Heparins on Fracture Healing

Toward the Clinical Use of Circulating Biomarkers Predictive of Bone Union

Contact Info

Product

Resources

About